Predict your next investment

Corporate Venture
leaps.bayer.com

See what CB Insights has to offer

Investments

52

Portfolio Exits

4

Partners & Customers

1

About Leaps by Bayer

Leaps by Bayer is a research institution in the healthcare and agriculture sector.

Leaps by Bayer Headquarter Location

Kaiser-Wilhelm-Allee 1

Nordrhein-Westfalen, 51368,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Leaps by Bayer

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Leaps by Bayer in 1 CB Insights research brief, most recently on Nov 6, 2019.

Latest Leaps by Bayer News

9am.health Closes $16M Series A

Apr 22, 2022

9am.health Closes $16M Series A   The latest round was co-led by 7Wire Ventures and Human Capital and included participation from new investors StartUp Health, Leaps by Bayer, and existing investors Define Ventures and Founders Fund. Frank WestermannCo-CEO9am.health 9am.health offers care to people living with prediabetes or type 2 diabetes via a direct-to-consumer model that provides a low-cost monthly subscription connecting the patient with a care team of licensed providers, pharmacists and nutritionists. Since launching last year, 9am.health has scaled quickly across 47 states and Washington, D.C., providing medical care, lab diagnostics, medications and personalized treatment plans to patients across a variety of backgrounds and demographics. Prediabetes and type 2 diabetes are two of the most prevalent chronic conditions in the U.S., collectively costing the nation hundreds of billions of dollars each year and creating thousands in medical expenses for individuals. Both populations are at significant risk of developing severe long-term health issues if their condition isn’t managed. Studies also have shown that people with diabetes are at higher risk of developing serious Covid-19 illness. “People want a new approach that fits with their busy lives, so 9am.health gives them a relationship-driven model that doesn’t sacrifice quality for lower cost,” said Frank Westermann, co-founder and co-CEO of 9am.health. ”Many on the 9am.health team, including myself and Co-CEO Anton Kittelberger live with diabetes and know firsthand how challenging it is to prioritize your health when the healthcare system doesn’t center around the patient,” Westermann added. “We’re removing the barriers that people face and are surrounding them with empathetic care.” Founded by Frank Westermann, Anton Kittelberger, Paul Geevarghese and Bernhard Schandl, 9am.health has rapidly expanded its services over the past few months. The company now offers a comprehensive subscription-based service that includes access to at-home diagnostic lab tests, blood glucose monitoring kits and physician-prescribed medications for prediabetes, type 2 diabetes and commonly associated conditions – all delivered directly and discreetly to patients’ homes. All members get personalized treatment plans that come with unlimited access to the 9am.health medical care team that can answer any patient need. 9am.health also provides non-members with at-home diabetes and prediabetes screenings at low costs. Glen TullmanManaging Partner7Wire Venture “The 9am.health team has created a new consumer-directed and comprehensive diabetes experience that includes medications, devices, labs, and care, provided by people who understand diabetes, all in one place. The pandemic demonstrated that health consumers are hungry for a new healthcare system that is responsive to their needs, improves care, and does so affordably,” said Glen Tullman, 7Wire Venture managing partner and CEO of Transcarent. “The 9am.health leadership team are entrepreneurs who are purpose-driven, passionate and are experienced in translating people’s needs into great experiences, and I’m looking forward to working with the team on their continued expansion.” Tullman is a veteran healthcare executive and investor who is passionate about transforming diabetes care globally. Previously the head of Livongo, which merged with Teladoc in 2020, he was familiar with the 9am.health leadership team’s prior experience building mySugr, a highly successful diabetes management app that was acquired by Roche in 2017. Tullman will now join 9am.health’s Board of Directors and will be instrumental in the company’s vision and market strategy moving forward. 9am.health has aggressive plans to grow its DTC business this year while also expanding to support the self-insured employer market, offering employees access to its virtual diabetes care program as a covered benefit. To help enable this expansion, 9am.health will use the new funding to grow its clinical and pharmacy services to include more medications and build out an ecosystem of medical device integrations and platform partners nationwide. 9am.health

Leaps by Bayer Investments

52 Investments

Leaps by Bayer has made 52 investments. Their latest investment was in 9am.health as part of their Series A on April 4, 2022.

CBI Logo

Leaps by Bayer Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/13/2022

Series A

9am.health

$16M

Yes

3

3/22/2022

Series A

Affini-T Therapeutics

$175M

Yes

17

3/17/2022

Series A - II

Triumvira Immunologics

$45M

No

5

3/15/2022

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/13/2022

3/22/2022

3/17/2022

3/15/2022

3/9/2022

Round

Series A

Series A

Series A - II

Series B - II

Series A

Company

9am.health

Affini-T Therapeutics

Triumvira Immunologics

Subscribe to see more

Subscribe to see more

Amount

$16M

$175M

$45M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

17

5

10

10

Leaps by Bayer Portfolio Exits

4 Portfolio Exits

Leaps by Bayer has 4 portfolio exits. Their latest portfolio exit was Senti Biosciences on December 20, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/20/2021

Acq - Pending

$99M

3

10/8/2021

IPO

Subscribe to see more

Subscribe to see more

10

6/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

4/16/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/20/2021

10/8/2021

6/21/2021

4/16/2021

Exit

Acq - Pending

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

Leaps by Bayer Partners & Customers

1 Partners and customers

Leaps by Bayer has 1 strategic partners and customers. Leaps by Bayer recently partnered with Temasek on August 8, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

8/12/2020

Partner

Singapore

Bayer and Temasek team up to develop vegetable varieties for vertical farming

Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio .

2

Date

8/12/2020

Type

Partner

Business Partner

Country

Singapore

News Snippet

Bayer and Temasek team up to develop vegetable varieties for vertical farming

Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio .

Sources

2

Leaps by Bayer Team

3 Team Members

Leaps by Bayer has 3 team members, including current Senior Director, Fabio Pucci.

Name

Work History

Title

Status

Fabio Pucci

Senior Director

Current

Ryan D. Teksten

Senior Director

Current

Karl Dane Wittrup

Senior Director

Current

Name

Fabio Pucci

Ryan D. Teksten

Karl Dane Wittrup

Work History

Title

Senior Director

Senior Director

Senior Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.